HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
12.48
-0.16 (-1.27%)
Aug 19, 2026, 2:01 PM EDT - Market open
HUTCHMED (China) Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 549.12 | 548.51 | 630.2 | 838 | 426.41 | 356.13 |
Revenue Growth | 0.11% | -12.96% | -24.80% | 96.53% | 19.73% | 56.21% |
Gross Profit Gross Profit Growth | 73.1 | 63.87 | 69.21 | 151.55 | -271.59 | -201.19 |
Operating Income Operating Income Growth | -34.78 | -39.16 | -43.71 | 18.38 | -407.69 | -328.32 |
Net Income Net Income Growth | 17.88 | 456.91 | 37.73 | 100.78 | -360.84 | -194.65 |
Earnings Per Share EPS Growth | 0.02 | 0.52 | 0.04 | 0.12 | -0.43 | -0.25 |
EPS Growth | -96.12% | 1200.03% | -66.28% | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Oncology/Immunology - Marketed Products Oncology/Immunology - Marketed Products Growth | 236.75 | 214.36 | 271.53 | 164.17 | 124.64 | - |
Oncology/Immunology - R&D Oncology/Immunology - R&D Growth | 67.66 | 71.18 | 91.83 | 364.45 | 39.2 | - |
Other Ventures Other Ventures Growth | 244.71 | 262.97 | 266.84 | 309.38 | 262.57 | 236.52 |
Total Total Growth | 549.12 | 548.51 | 630.2 | 838 | 426.41 | 356.13 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,376 | 1,369 | 837.98 | 889.02 | 633.34 | 1,014 |
Total Debt Total Debt Growth | 94.51 | 97.89 | 89.82 | 86.13 | 27.01 | 38.98 |
Net Cash (Debt) Net Cash Growth | 1,282 | 1,271 | 748.16 | 802.88 | 606.33 | 975.48 |
Net Cash Growth | 0.86% | 69.89% | -6.82% | 32.42% | -37.84% | 142.21% |
Net Cash Per Share Net Cash Per Share Growth | 1.47 | 1.46 | 0.86 | 0.92 | 0.72 | 1.23 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 20.46 | -64.66 | 0.5 | 219.26 | -268.6 | -204.22 |
Capital Expenditures CapEx Growth | -10.51 | -14.15 | -17.93 | -32.61 | -36.66 | -16.4 |
Free Cash Flow Free Cash Flow Growth | 9.95 | -78.81 | -17.44 | 186.65 | -305.26 | -220.62 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 13.31% | 11.64% | 10.98% | 18.09% | -63.69% | -56.49% |
Operating Margin | -6.33% | -7.14% | -6.93% | 2.19% | -95.61% | -92.19% |
Pretax Margin | 3.66% | 95.05% | 7.20% | 12.60% | -84.58% | -43.56% |
Profit Margin | 3.26% | 83.30% | 5.99% | 12.03% | -84.62% | -54.66% |
FCF Margin | 1.81% | -14.37% | -2.77% | 22.27% | -71.59% | -61.95% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 124.36 | 5.27 | 66.65 | 30.53 | - | - |
P/FCF Ratio | 223.54 | - | - | 16.48 | - | - |
PS Ratio | 4.05 | 4.39 | 3.99 | 3.67 | 6.30 | 17.26 |